secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emmaus Life Sciences, Inc. (EMMA)
CIK:        0000822370
Form:       8-K
Filed at:   2026-03-04T23:59:59+00:00
Accession:  0001213900-26-023644
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emmaus enters Exclusive Supply Agreement with NeoImmuneTech for Endari in US/Canada
--------------------------------------------------------------------------------

- Agreement dated March 2, 2026; Emmaus to supply Endari (L-glutamine) exclusively to NIT for sickle cell disease in US and Canada.
- Supply price is Emmaus' production cost plus a specified double-digit percentage margin.
- Effective Date contingent on NIT obtaining necessary regulatory approvals and licensing; must occur by October 1, 2026.
- Either party may terminate if Effective Date does not occur by Oct 1, 2026 (unless due to Emmaus' wrongful acts).
- Exclusive Supply Agreement is a follow-up to the License Agreement reported on December 31, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/822370/000121390026023644/0001213900-26-023644-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/822370/000121390026023644/ea0280016-8k_emmaus.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-023644

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer